STOCK TITAN

Spectral AI, Inc. - $MDAI STOCK NEWS

Welcome to our dedicated page for Spectral AI news (Ticker: $MDAI), a resource for investors and traders seeking the latest updates and insights on Spectral AI stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Spectral AI's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Spectral AI's position in the market.

Rhea-AI Summary

Spectral AI (Nasdaq: MDAI), an AI-driven medical diagnostics firm, announced its scheduled inclusion in the Russell Microcap® Index following the 2024 Russell US Indexes reconstitution, effective June 28, 2024. The company's proprietary DeepView™ System, which assesses wound healing potential, received UKCA Authorization and is expected to generate its first commercial revenue later in 2024. Spectral AI was also awarded a $150 million contract from the US Government for the DeepView™ System's advanced development. For Q1 2024, the company reported a 24.6% increase in R&D revenue, totaling $6.3 million, and a cash position of $10.2 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.97%
Tags
AI
-
Rhea-AI Summary

Spectral AI (Nasdaq: MDAI), an AI company specializing in medical diagnostics for wound care, announced its participation in Benzinga’s “AI Unleashed: Exploring the Possibilities” virtual event on May 30, 2024. CEO Peter M. Carlson will represent the company in a fireside chat starting at 11:25 am ET. The event will be live-streamed and accessible through the company's investor portal. This event serves as a platform for Spectral AI to showcase its advancements and future prospects in AI-driven medical diagnostics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
conferences AI
-
Rhea-AI Summary

Spectral AI announced that its officers and directors purchased approximately 113,000 shares of its common stock in open market transactions on May 10 and May 15, 2024. The company is progressing toward commercializing its AI-driven DeepView™ System, which assesses wound healing potential, with initial applications in burns and diabetic foot ulcers. After receiving UKCA Authorization in February, Spectral AI plans to generate its first commercial product revenue in the second half of 2024. The company continues to advance clinical studies in the US and UK and aims to file additional regulatory submissions in 2024 and 2025. A $150 million multi-year contract from the US Government was awarded in September 2023 for the DeepView™ System's development, contributing to a total of $250 million in non-dilutive support. For Q1 2024, Research & Development revenue rose by 24.6% to $6.3 million, improving the company's cash position to $10.2 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.76%
Tags
AI
Rhea-AI Summary

Spectral AI (Nasdaq: MDAI) announced the results of its 2024 Annual Meeting of Stockholders held on May 14, 2024. Key outcomes include the election of six directors to serve until the next Annual Meeting, and the approval of four proposals. Newly elected directors are Richard Cotton, Peter M. Carlson, Dr. J. Michael DiMaio, Martin Mellish, Deepak Sadagopan, and Marion Snyder. Additionally, stockholders ratified the adoption of the 2023 Long Term Incentive Plan, the appointment of KPMG LLP as the company's independent auditor for the 2024 fiscal year, and the reservation and issuance of shares of common stock pursuant to the Standby Equity Purchase Agreement. The Board also expanded to seven members and appointed Erich Spangenberg as a new director, who had previously declined to stand for reelection but accepted the Board’s request to serve.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.39%
Tags
management AI
-
Rhea-AI Summary

Spectral AI, Inc. (Nasdaq: MDAI) announced their Q1 2024 financial results, showcasing a $6.3 million Research & Development revenue, cash reserves of $10.2 million, and the deployment of DeepView AI®-Burn devices in the UK with expected commercial revenue in 2H 2024. The company plans further regulatory submissions in the US and UK for the DeepView™ System in 2024 and 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.58%
Tags
-
Rhea-AI Summary

Spectral AI, Inc. (Nasdaq: MDAI) will be participating in the Sidoti Micro-Cap Virtual Investor Conference on May 8-9, 2024. The company focuses on AI for medical diagnostics in wound care. Interested parties can access the live presentation and webcast on the company's website. Registration for the event is free.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.91%
Tags
conferences AI
Rhea-AI Summary

Spectral AI, Inc. (Nasdaq: MDAI) received the Commitment to Quality Achievement Award from the Texas Manufacturer Assistance Center for their UKCA Mark Attainment. The award recognizes the company's leadership in the Texas Manufacturing space and their dedication to innovation in wound care through DeepView™ technology. TMAC, associated with MEP-NIST, supports Texas manufacturers with business consulting, technology implementation, workforce development, and strategic planning.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.37%
Tags
AI
-
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) has scheduled its 2024 first quarter financial results release for May 7, 2024. The company specializes in AI for medical diagnostics in wound care, aiming for faster and more precise treatment decisions. Investors can join the conference call at 5:00 pm Eastern Time to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
-
Rhea-AI Summary
Spectral AI appoints Erich Spangenberg as CEO of its health care IP-focused subsidiary, Spectral IP, aiming to unlock additional value for MDAI shareholders through potential spin-off. Spangenberg's IP monetization expertise and investment plans highlight the company's strategic move towards IP-related opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.09%
Tags
AI
Rhea-AI Summary
Spectral AI, Inc. appoints Jeremiah A. Sparks as Chief Commercialization Officer to drive commercialization of DeepView, an innovative wound management solution. Sparks brings over 20 years of medical device marketing experience, including global marketing and business strategy. His track record includes successful market assessments, commercialization plans, and product launches at major companies like Johnson & Johnson and Allergan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.39%
Tags
management AI
Spectral AI, Inc.

Nasdaq:MDAI

MDAI Rankings

MDAI Stock Data

29.02M
7.40M
56.82%
16.31%
1.1%
Medical Devices
Healthcare
Link
United States of America
DALLAS